Disease-specific and glucocorticoid-responsive serum biomarkers for Duchenne Muscular Dystrophy-Reference-Cited by-同舟云学术

Disease-specific and glucocorticoid-responsive serum biomarkers for Duchenne Muscular Dystrophy

Published:2019-08-21 Issue:1 Volume:9 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Hathout Yetrib,Liang Chen,Ogundele Michael,Xu Ganggang,Tawalbeh Shefa M.,Dang Utkarsh J,Hoffman Eric P.,Gordish-Dressman Heather,Conklin Laurie S.,van den Anker John N.,Clemens Paula R.,Mah Jean K.,Henricson Erik,McDonald Craig

Funder

United States Department of Defense | United States Army | Army Medical Command | Congressionally Directed Medical Research Programs

U.S. Department of Health & Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development

Muscular Dystrophy Association

U.S. Department of Defense

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41598-019-48548-9.pdf

Reference51 articles.

1. Ayoglu, B. et al. Affinity proteomics within rare diseases: a BIO-NMD study for blood biomarkers of muscular dystrophies. EMBO Molecular Medicine 6(7), 918–936 (2014).

2. Hathout, Y. et al. Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy. Proceedings of the National Academy of Sciences 112, 7153–7158 (2015).

3. Spitali, P. et al. Tracking disease progression non-invasively in Duchenne and Becker muscular dystrophies. Journal of Cachexia, Sarcopenia and Muscle 9(4), 715–726 (2018).

4. Cacchiarelli, D. et al. miRNAs as serum biomarkers for Duchenne muscular dystrophy. EMBO Molecular Medicine 3(5), 258–265 (2011).

5. Li, X. et al. Circulating Muscle-specific miRNAs in Duchenne Muscular Dystrophy Patients. Molecular Therapy - Nucleic Acids 3, e177 (2014).

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Large scale serum proteomics identifies proteins associated with performance decline and clinical milestones in Duchenne muscular dystrophy;2024-08-07

2. “If you cannot measure it, you cannot improve it”. Outcome measures in Duchenne Muscular Dystrophy: current and future perspectives;Acta Neurologica Belgica;2024-07-31

3. Moderate-term dimethyl fumarate treatment reduces pathology of dystrophic skeletal and cardiac muscle in a mouse model;2024-07-17

4. Recent Advances in Pre-Clinical Development of Adiponectin Receptor Agonist Therapies for Duchenne Muscular Dystrophy;Biomedicines;2024-06-25

5. Serum protein and imaging biomarkers after intermittent steroid treatment in muscular dystrophy;2024-06-16